Clinical trials: Extraosseous Ewing's Sarcoma (EOE)
Ewing's Sarcoma, Primitive Neuroectodermal Tumor (PNET)
Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy
This is a phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis® (PM00104) in Patients with Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One…
- Conditions
- Ewing's Sarcoma, Primitive Neuroectodermal Tumor (PNET), Askin's Tumor of the Chest Wall, Extraosseous Ewing's Sarcoma (EOE)
- Trial name
- NCT01222767
- Testing
- Zalypsis
- Where
- 7 sites in United States, France and 1 more
- Volunteers
- 17 people
- Sponsor
- PharmaMar
Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
This trial examined the outcome benefit to patients of adding a new chemotherapy drug combination to the established treatment approach for patients with extracranial Ewing sarcoma, that had not spread from the primary site to…
- Conditions
- Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
- Trial name
- NCT01231906
- Testing
- Cyclophosphamide, Dexrazoxane, Doxorubicin Hydrochloride
- Where
- 243 sites in United States, Australia and 4 more
- Volunteers
- 642 people
- Sponsor
- Children's Oncology Group
Cancer
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
RATIONALE: Cyproheptadine hydrochloride may prevent weight loss caused by cancer or cancer treatment. It is not yet known whether cyproheptadine is more effective than a placebo in preventing weight loss in young patients…
- Trial name
- NCT01132547
- Testing
- cyproheptadine hydrochloride
- Where
- 14 sites in United States
- Volunteers
- 22 people
- Sponsor
- University of South Florida
Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma
Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma
This phase II trial study has a 6-patient feasibility portion studying the tolerability of chemotherapy with vincristine sulfate together with topotecan hydrochloride, cyclophosphamide, and bevacizumab in treating young patients…
- Conditions
- Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Trial name
- NCT00516295
- Testing
- topotecan hydrochloride, vincristine sulfate, cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)